Bionano Genomics, Inc.

BNGO Healthcare Medical Instruments & Supplies

Bionano Genomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.5 million, down 7.37% from fiscal 2024. In the quarter to June 2026, revenue grew 21.4%, EPS grew 67.8%, free cash flow fell 33.9% and total debt fell 1.91%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.25 0.12 −8.76%
Market cap
$16.1M
P/E
0.0×
Fwd P/E
−0.6×
Dividend yield
—
F-score
5/9
Altman Z
−14.26
Beneish M
−3.39
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— — 2 3 3 4 2 3 3 5
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
— — (3.93) (6.75) 3.07 11.81 1.93 (6.39) (16.38) (14.26)
P/S ratio
0.00 0.00 3.09 1.84 37.84 46.11 15.01 1.89 0.72 0.29
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(16.50) (39.84) (9.48) (16.27) (6.48) 9.97 0.52 (13.50) (37.51) (31.33)
Beneish M-Score
— (3.06) (1.51) (2.44) 17,663.44 (0.79) (2.21) (5.75) 5.24 (3.39)
P/Operating CF
(6.97) (6.97) (9.07) (1.98) (26.58) (32.36) (12.09) (2.29) (3.40) (2.00)
P/B ratio
0.00 0.00 3.66 5.15 9.17 2.46 1.67 0.71 0.63 0.19
Price to Tangible BV
0.00 0.00 3.66 5.15 12.17 3.26 3.19 1.10 0.86 0.21
EV/Sales
0.00 0.00 2.52 3.96 36.91 33.17 11.58 (0.44) 0.63 (0.12)
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.13 0.00 0.14
EV/Operating CF
(0.72) (0.72) (1.51) (1.36) (8.19) (8.29) (2.58) 0.13 (0.28) 0.21
EV/FCF
(0.69) (0.69) (1.49) (1.36) (8.18) (8.20) (2.53) 0.12 (0.28) 0.21
Quick Ratio
0.76 0.26 4.65 0.90 4.61 11.70 3.35 1.11 0.68 1.51
Current Ratio
1.15 0.43 5.09 1.07 5.23 12.47 4.38 1.40 1.06 1.98
Net Debt/EBITDA
(0.07) (0.26) 0.39 (0.11) 0.60 3.36 0.90 0.79 0.24 1.06
Debt/Assets
44.86% 66.33% 36.41% 66.49% 27.01% 0.97% 1.18% 1.67% 4.62% 4.73%
Debt/Equity
(0.24) (0.13) 0.89 5.56 0.47 0.01 0.01 0.04 0.10 0.08
Asset Turnover
0.54 0.76 0.69 0.37 0.19 0.08 0.08 0.14 0.21 0.38
Operating CF/Net income
1.25 0.89 1.08 0.99 0.93 0.99 0.94 0.54 0.62 0.62
Capex/Depreciation
(1.21) (0.68) (0.25) (0.05) 0.00 (0.22) (0.24) (0.02) 0.00 0.00
Interest Coverage
(45.03) (39.29) (14.78) (11.32) (15.30) (83.17) (441.94) (42.05) — —
ROE
48.65% 60.31% 92.27% (433.64%) (212.46%) (38.92%) (45.21%) (134.56%) (170.33%) (66.15%)
ROA
(151.19%) (187.43%) (105.85%) (108.40%) (90.68%) (33.11%) (38.74%) (89.09%) (76.97%) (35.13%)
ROIC
0.00% 0.00% (482.56%) (253.19%) (185.94%) (53.45%) (58.86%) 0.00% (352.46%) (113.43%)
Return on Tangible Assets
(347.50%) 359.08% (91.21%) (776.27%) (96.15%) (27.76%) (95.09%) (366.51%) (524.33%) (70.78%)
Average Days of Receivables
99.22 128.73 137.30 228.24 119.12 100.16 92.19 94.18 56.36 66.58
Research and Development Expense of Revenue
168.29% 126.35% 79.03% 89.65% 120.62% 125.05% 176.42% 149.61% 80.59% 39.90%
Selling, General and Administrative Expense of Revenue
190.65% 148.13% 118.50% 198.98% 365.38% 325.29% 318.67% 256.83% 168.49% 123.30%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.14 0.22 0.39 0.16 0.13 0.06
Share Based Compensation of Revenue
1.92% 4.03% 10.91% 13.29% 18.28% 54.05% 80.63% 42.03% 31.64% 15.90%
Graham Net Nets
0.52 0.52 0.23 0.09 0.07 0.28 0.24 0.32 (0.08) 1.95
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(68.78%) (68.78%) (64.65%) (160.87%) (17.17%) (8.68%) (31.88%) (339.47%) (508.59%) (311.11%)
Free Cash Flow Yield
(153.71%) (153.71%) (54.65%) (159.15%) (11.93%) (8.77%) (30.48%) (185.81%) (312.11%) (197.43%)
Revenue per Share
67,928.00 2,112.22 1,017.01 405.18 48.84 38.90 57.56 63.47 24.21 5.24
Operating CF per Share
(234,964.00) (4,626.18) (1,690.16) (1,181.19) (220.07) (155.62) (258.42) (220.00) (54.23) (3.00)
Capex per Share
(13,499.00) (226.18) (28.11) (2.44) 0.00 (1.78) (5.14) (2.97) (0.08) 0.00
Free Cash Flow per Share
(248,463.00) (4,852.36) (1,718.27) (1,183.63) (220.07) (157.40) (263.56) (222.97) (54.31) (3.00)
Cash per Share
52,496.00 227.09 1,400.23 692.46 220.84 542.22 234.34 179.07 16.11 5.42
Shareholders Equity per Share
(272,590.00) (11,161.60) 859.10 144.55 201.50 729.38 516.35 168.99 27.83 8.16
Interest Debt per Share
0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
(272,590.00) (11,161.60) 859.10 144.55 201.50 729.38 516.35 168.99 27.83 8.16
Free Cash Flow
(24.85) (21.84) (20.28) (29.59) (38.31) (72.75) (127.30) (126.87) (69.02) (16.34)
Working Capital
1.37 (9.51) 18.50 1.89 37.84 250.57 121.41 40.09 2.15 22.44
Capital Expenditures
(1.35) (1.02) (0.33) (0.06) — (0.82) (2.48) (1.69) (0.10) —
Net Current Asset Value
(31.31) (53.23) 8.36 1.66 21.42 232.43 99.19 21.87 (1.81) 16.23
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.00 0.10
Capex to Sales
0.20 0.11 0.03 0.01 0.00 0.05 0.09 0.05 0.00 0.00
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.28 0.50 0.74 0.58 0.30 0.36 0.58 3.88 1.74 0.59
Cash ROIC
161.59% 51.41% (56.81%) (72.15%) (42.64%) (12.30%) (34.76%) (62.92%) (116.23%) (21.11%)
Accounts Receivable Turnover
2.61 3.66 3.05 1.87 1.87 4.66 4.65 4.42 4.37 5.73
Accounts Payable Turnover
2.31 3.90 4.77 3.34 2.04 2.06 1.88 2.32 3.50 2.44
Inventory Turnover
1.80 3.45 6.31 3.00 1.70 1.80 1.04 1.01 1.79 1.85
Average Days of Payables
80.81 139.39 56.64 145.57 186.64 278.63 209.31 142.76 83.60 133.16
Days of Inventory on Hand
183.32 102.51 44.77 185.71 211.16 320.50 496.99 314.71 133.54 129.77
Average Receivables
2.60 2.60 3.93 5.42 4.55 3.85 5.98 8.17 7.04 4.98
Average Payables
1.55 1.55 1.83 2.03 2.81 6.85 11.65 11.46 8.67 6.28
Average Inventory
1.99 1.75 1.38 2.26 3.38 7.85 21.07 26.33 17.01 8.28
Average Assets
12.47 12.47 17.47 27.51 45.33 218.78 342.30 260.95 145.54 75.13
Average Common Equity
(38.74) (38.74) (20.04) 6.88 19.35 186.10 293.26 172.78 65.77 39.90

Fold the line items

Columns are period end dates